Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
作者： Peter J. Weiden , George M. Simpson , Steven G. Potkin , Richard L. O’Sullivan
DOI: 10.4088/JCP.V64N0514
关键词:
摘要: … Ziprasidone is the fifth atypical antipsychotic introduced in the United … of schizophrenia and schizoaffective disorder.In addition to improving positive and negative symptoms, ziprasidone …
psychiatrist.com
sci-hub.st 参考文章(16)
Ralph Aquila, Janet M. Standard, Laura Dalheim, Peter J. Weiden, Switching antipsychotic medications. The Journal of Clinical Psychiatry. ,vol. 58, pp. 63- 72 ,(1997)
McEvoy Jp, Expert Consensus Guideline Series Treatment of Schizophrenia 1999 Physicians Postgraduate Press. ,(1999)
Bruce J. Kinon, Bruce R. Basson, Julie A. Gilmore, Sandra Malcolm, Virginia L. Stauffer, Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. The Journal of Clinical Psychiatry. ,vol. 61, pp. 833- 840 ,(2000) , 10.4088/JCP.V61N1105
Donald C. Goff, Thomas Posever, Lawrence Herz, Jeffrey Simmons, Nicholas Kletti, Katherine Lapierre, Keith D. Wilner, C. Gordon Law, Grant N. Ko, An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder Journal of Clinical Psychopharmacology. ,vol. 18, pp. 296- 304 ,(1998) , 10.1097/00004714-199808000-00009
Thomas R. E. Barnes, A rating scale for drug-induced akathisia. British Journal of Psychiatry. ,vol. 154, pp. 672- 676 ,(1989) , 10.1192/BJP.154.5.672
D Daniel, Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial Neuropsychopharmacology. ,vol. 20, pp. 491- 505 ,(1999) , 10.1016/S0893-133X(98)00090-6
G. Simpson, R.L. O'Sullivan, C. Siu, Ziprasidone vs olanzapine in schizophrenia: Results of a double-blind trial European Neuropsychopharmacology. ,vol. 11, ,(2001) , 10.1016/S0924-977X(01)80342-4
Ashok K. Malla, Ross M.G. Norman, Vinod Kotteda, Sandra Zirul, Switching from therapy with typical antipsychotic agents to risperidone: Long-term impact on patient outcome Clinical Therapeutics. ,vol. 21, pp. 806- 817 ,(1999) , 10.1016/S0149-2918(99)80003-4
P. Keck Jr, Alan Buffenstein, James Ferguson, John Feighner, William Jaffe, Edmund P. Harrigan, Marilyn R. Morrissey, Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial Psychopharmacology. ,vol. 140, pp. 173- 184 ,(1998) , 10.1007/S002130050755
M. Arato, R. O’Connor, J.E. Bradbury, H. Meltzer, Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia European Psychiatry. ,vol. 13, ,(1998) , 10.1016/S0924-9338(99)80610-5